Kevin O'reilly Net Worth

The estimated Net Worth of Kevin O'reilly is at least 38.5 千$ dollars as of 16 February 2021. Kevin reilly owns over 1,528 units of Varian Medical Systems stock worth over 38,527$ and over the last 4 years Kevin sold VAR stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kevin reilly VAR stock SEC Form 4 insiders trading

Kevin has made over 1 trades of the Varian Medical Systems stock since 2021, according to the Form 4 filled with the SEC. Most recently Kevin exercised 1,528 units of VAR stock worth 25,265$ on 16 February 2021.

The largest trade Kevin's ever made was exercising 1,528 units of Varian Medical Systems stock on 16 February 2021 worth over 25,265$. On average, Kevin trades about 382 units every 0 days since 2020. As of 16 February 2021 Kevin still owns at least 2,330 units of Varian Medical Systems stock.

You can see the complete history of Kevin reilly stock trades at the bottom of the page.

Insiders trading at Varian Medical Systems

Over the last 22 years, insiders at Varian Medical Systems have traded over 57,574,967$ worth of Varian Medical Systems stock and bought 500 units worth 22,595$ . The most active insiders traders include Kent J Thiry、Timothy E Guertin、Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of 181,124$. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth 1,142,589$.

What does Varian Medical Systems do?

Complete history of Kevin reilly stock trades at Varian Medical Systems

Varian Medical Systems executives and stock owners

Varian Medical Systems executives and other stock owners filed with the SEC include:

• Dow Wilson,
  Chief Executive Officer, Director
• Kolleen Kennedy,
  President - Proton Solutions Division and Chief Growth Officer
• Chris Toth,
  President, Chief Operating Officer
• R. Andrew Eckert,
  Independent Chairman of the Board
• Jeffrey Balser,
  Independent Director
• Judy Bruner,
  Independent Director
• Anat Ashkenazi,
  Independent Director
• Jean-Luc Butel,
  Independent Director
• Regina Dugan,
  Independent Director
• David Illingworth,
  Independent Director
• Phillip Febbo,
  Independent Director
• Michael Hutchinson,
  Senior Vice President, Chief Legal Officer
• Francis Facchini,
  President, Interventional Solutions Business
• Anshul Maheshwari,
  Vice President, Treasurer and Investor Relations
• Michelle Le Beau,
  Independent Director
• J. Michael Bruff,
  Chief Financial Officer, Senior Vice President - Finance
• Magnus Momsen,
  SVP, CAO, Corporate Controller
• Mark R Laret,
  Director
• Jose Baselga,
  Director
• John W Kuo,
  SVP, Gen Counsel and Secretary
• Gary E Jr Bischoping,
  SVP, Finance & CFO
• Susan L Bostrom,
  Director
• Timothy E Guertin,
  Director
• Clarence R Verhoef,
  SVP, Finance, Corp Controller
• Venkatraman Thyagarajan,
  Director
• Sunny Sanyal,
  SVP and President, ICB
• Robert H Kluge,
  Corporate Vice President
• Richard M Levy,
  President and CEO
• Ruediger Naumann Etienne,
  Director
• John Seely Brown,
  Director
• Erich R Reinhardt,
  Director
• Tai Yun Chen,
  VP and Corporate Controller
• David W Jr Martin,
  Director
• Steven A Leibel,
  Director
• Kent J Thiry,
  Director
• Allen S Lichter,
  Director
• Samuel Hellman,
  Director
• Crisanto C Raimundo,
  Corporate Controller
• Terry R Lautenbach,
  Director
• Joseph B Phair,
  VP Admin,Gen Counsel,Secretary
• Elisha W Finney,
  Corporate Vice President & CFO
• Kevin O'reilly,
  SVP, President of Oncology Sys